Friday, December 12, 2025

Levacetylleucine treatment of Niemann-Pick disease type C

N-acetyl-L-leucine (Levacetylleucine) normalizes Transcription Factor EB (TFEB) activity by stereospecific bidirectional modulation
Lianne C. Davis, Rebecca Braine, Grant C. Churchill, Mallory Factor, Taylor Fields, Marc Patterson, Frances Platt, Michael Strupp, Antony Galione. bioRxiv 2025.11.30.691375; doi: https://doi.org/10.64898/2025.11.30.691375

This article is a preprint and has not been certified by peer review

Abstract

Levacetylleucine (AqneursaTM), a chemically modified amino acid, is the only US Food and Drug Administration-approved monotherapy for the treatment of Niemann-Pick disease type C (NPC) (Beninger, 2024; Mullard, 2024; van Gool et al., 2025). This acetylated derivative of L-leucine functions as a pro-drug, with the acetyl group rendering it a substrate for the monocarboxylate transporter (MCT) family of transporters to allow appreciable penetration of the blood-brain barrier and its efficient uptake into cells (Churchill et al., 2021). Inside cells, levacetylleucine undergoes metabolism catalysed by acylases, and the resultant high quantities of L-leucine enter metabolic pathways which enhance mitochondrial bioenergetics and, as previously demonstrated, indirectly ameliorate lysosomal function (Kaya et al., 2020). Here, we show a novel aspect of levacetylleucine’s mechanism of action, demonstrating a direct effect on lysosomal function through its rapid modulation of the translocation of the transcription factor TFEB, a master regulator of lysosomal biogenic and autophagic genes (Napolitano and Ballabio, 2016), from cytoplasm to nucleus. Uniquely, we have demonstrated a biphasic action whereby levacetylleucine normalizes TFEB activity, consistent with levacetylleucine’s previously shown ability to regulate cellular homeostasis: in wild-type HeLa cells, levacetylleucine enhances and activates the translocation of TFEB to the nucleus. In contrast, in cellular models of NPC type 1 disease, where TFEB is already over-expressed in the nucleus (as the cell attempts to compensate for the primary defect by activating TFEB as a natural cellular response to the lysosomal substrate accumulation and associated cellular stress), treatment with levacetylleucine down-regulates and restores the distribution of TFEB to a more normalized cytoplasmic: nuclear ratio. Importantly, both effects of levacetylleucine occur at concentrations consistent with plasma concentrations in therapeutic dosing (Churchill et al., 2020). The effects were also confirmed to be stereospecific to the L-enantiomer, as neither the D-enantiomer (N-acetyl-D-leucine) or racemate (N-acetyl-DL-leucine) had any effect, The presence of the D-enantiomer in the racemic mixture inhibited the ability of levacetylleucine to promote TFEB bidirectional translocation, consistent with previous studies, which have established antagonism of N-acetyl-L-leucine by N-acetyl-D-leucine in the racemic mixture (rendering the racemic mixture without effect). This bidirectional mechanism of action of levacetylleucine to impact lysosomal function directly and normalize, either by activating basal TFEB signalling or reducing aberrant TFEB function in NPC1 knockout cells, thereby modulating lysosomal and autophagic functions, lends itself to the treatment of a broad range of neurological and neurodevelopment disorders.

Thursday, December 11, 2025

Physicians receiving payments are more likely to prescribe the company’s drugs

Sayed A, Gupta R, Ramachandran R, et al. Industry payments to US neurologists related to multiple sclerosis drugs and prescribing (2015–2019): a retrospective cohort study. BMJ Open 2025;15:e095952. doi: 10.1136/bmjopen-2024-095952

Abstract

Objectives To measure the prevalence and magnitude of industry payments to neurologists prescribing multiple sclerosis (MS) drugs and determine whether payments are associated with prescribing.

Design Retrospective observational study.

Setting Data on neurologists prescribing MS drugs from 2015 to 2019 in the Medicare Part D database linked to the Centers for Medicare & Medicaid Services Open Payments database.

Participants 7401 neurologists prescribing MS drugs from 2015 to 2019 to Medicare beneficiaries.

Main outcome measures The primary outcome was the proportion of physicians’ annual prescriptions manufactured by a given company. Generalised linear mixed models were used to evaluate associations between the presence and magnitude of payments and prescribing. The association between prescription volume and the likelihood of receiving payments as well as the value of payments was also assessed.

Results Among 7401 neurologists, 5809 (78.5%) received payments totalling US$163.6 million between 2015 and 2019. While the median amount per physician was US$779 (IQR, US$188–US$2587), US$155.7 million (95.2%) accrued to the top 10% of payment recipients. Higher prescription volumes were associated with a higher likelihood of receiving any payment type, particularly for consulting services, non-consulting services and travel/lodging (p<0.001). Among payment recipients, the amount received was positively associated with prescription volume (p<0.001). Receipt of payments was associated with greater likelihood of prescribing the company’s drugs compared with those who received no payments from that company (OR 1.13 (95% CI 1.11 to 1.15)), with the largest association for non-consulting services, such as being a speaker at an event (OR 1.53 (95% CI 1.44 to 1.62)). Larger payments were associated with a greater likelihood of prescribing (OR 1.10, 1.26, 1.29 and 1.50 for US$50, US$500, US$1000 and US$5000, respectively), as were longer durations of payments (OR 1.12 for single year to 1.78 for 5 consecutive years) and more recent payments (OR 1.03 for payments made 4 years prior to 1.34 for payments made in the same year).

Conclusions Nearly 80% of neurologists prescribing MS drugs received at least one industry payment, with higher volume prescribers being more likely to receive payments. Physicians receiving payments were more likely to prescribe the company’s drugs, with a stronger association for payments that were larger, sustained and recent.
________________________________________________________________

A ‘Humbling’ Study

Two MS neurologists without ties to the research—Elizabeth Silbermann, MD, an assistant professor of neurology at Oregon Health & Sciences University (OHSU), and Mitchell Wallin, MD, MPH, FAAN, associate professor of neurology at the University of Maryland School of Medicine and director of the VA MS Center of Excellence—said Dr. Ross and his team made a good analysis of the data available to them.

“It's a good population-based sample of the United States with high numbers,” said Dr. Wallin, who thought it was wise that the researchers stopped the analysis at the beginning of the pandemic. He added that he was impressed that the study showed a dose-response relationship between payments and prescribing. “I think that it's a humbling article.”

Dr. Silberman called it a broad study that “captured data in the best way you can in the United States.” She said the high percentage of neurologists who accepted pharma money had a “bit of shock value.”
The data problem, which the researchers acknowledged, is that the study was limited to prescribing information from Medicare Part D. MS tends to be diagnosed among much younger people, so the study may have missed those just starting medications as well as some younger people with aggressive disease.

In addition, Dr. Wallin said that many MS experts at academic medical centers are now trying to wean older, stable patients from their medications. And newer infusion drugs are paid through Medicare Part B, so Part D data does not capture them.

Dr. Ross acknowledged that the data his team used skewed toward older patients and young ones with serious disabilities. However, the MS specialists included in the study also treat younger patients, and he thinks their prescribing habits likely transcended age. It is possible that industry influence on prescribing behavior is even more pronounced among younger patients because they change drugs more frequently, he said.

Dr. Wallin pointed out that insurance companies often resist paying for newer, more expensive drugs, which may mean that doctors end up prescribing medications that were not their first or even second choice.

Earlier this year, Dr. Silbermann's colleagues at OHSU published a study on uptake of generic glatiramer acetate and industry payments that found an association between the payments and prescriptions for the branded drug. Although generics became available in 2015, more than half of prescriptions in 2021 were still for the branded formulation. Neurologists who received industry payments were more likely to prescribe the branded drug, the study found.
One confounding factor, Dr. Silbermann said, is that drug companies often provide financial assistance for patients who take the branded drug.

Why Does This Problem Persist?

Asked why doctors continue to accept payments from drug companies when multiple studies have shown that it affects prescribing behavior, Dr. Ross said he has heard from other doctors that they don't think payments can influence them. Also, it's part of medical culture. Doctors think, “Everyone's doing it, so why shouldn't I?” he said.

Dr. Wallin, who does not accept direct payments from pharma, agreed that most physicians “believe that pharmaceutical reps don't really affect their behavior,” but “people are avaricious. That's the short answer.”

Unfortunately, he said, medical groups depend on industry to support their large, educational meetings, and he and Dr. Silbermann agreed that talking to sales reps can be valuable. She occasionally attends educational events sponsored by a drug company but doesn't eat or drink, except for a cappuccino she might accept from a drug company at a big meeting. Dr. Silbermann said she understands why hungry, time-pressed convention-goers might accept some food, though.

The big issue, she said, is that doctors need information about drugs, and it's hard to get it from primary sources. Keeping up to date on more than 20 medications might require reading 50 papers a year.
“Pharma picked up on a gap in the field, which is that physicians need to receive high-quality information in order to inform their practices,” she said. “It's really hard to receive high-quality information for free these days. Conferences are incredibly expensive.”

While many payments are small, they add up over time. Dr. Ross believes companies wouldn't spend the money if they didn't think the tactic was working.

“These companies aren't making these payments for nothing,” he said.

He had hoped that federal rules requiring disclosure of payments would make physicians stop taking them. At first, doctors worried about having their names and payment amounts made public. The information has been used for research, but fears of widespread embarrassment have not materialized.
“For the most part, it's kind of out of sight, out of mind,” said Dr. Ross, adding that half measures are unlikely to make a dent in the problem. “I think companies continue to engage in these practices because physicians engage in these practices. The way you would fix it would be to declare all payments to be in violation of kickback statutes and say they're illegal.” Current government guidance, he added, is “fuzzy.”

While Dr. Wallin thinks it makes sense to limit contact between drug company representatives and doctors in clinical practice, he wouldn't want to cut off all communication between drug makers and physicians. It's helpful to discuss side effects with company employees, he said. A middle ground might be an educational nonprofit that could accept pharma money but would not tie specific talks to an individual company, Dr. Wallin said.

National conferences, along with podcasts and journal groups from the AAN, can help physicians stay informed, Dr. Silbermann noted. A good starting point for further improvements, she said, would be for neurologists to raise awareness that an educational gap needs to be filled in a way that's less likely to influence physician decision-making.

Disclosures:
Dr. Ross was an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled September 2022. He currently receives research support through Yale University from Johnson & Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Greenwall Foundation, and from Arnold Ventures. Dr. Wallin is a principal investigator on a Sanofi-sponsored randomized controlled drug trial and received travel funding as a speaker from CMSC.

https://neurologytoday.aan.com/doi/10.1097/01.wnt.0001173580.24350.4e

Wednesday, December 10, 2025

ANKLE2 autosomal recessive congenital microcephaly

Inspired by sibling patients

Fishburn AT, Florio CJ, Lopez NJ, Link NL, Shah PS. Molecular functions of ANKLE2 and its implications in human disease. Dis Model Mech. 2024 Apr 1;17(4):dmm050554. doi: 10.1242/dmm.050554. Epub 2024 May 1. PMID: 38691001; PMCID: PMC11103583.

Abstract

Ankyrin repeat and LEM domain-containing 2 (ANKLE2) is a scaffolding protein with established roles in cell division and development, the dysfunction of which is increasingly implicated in human disease. ANKLE2 regulates nuclear envelope disassembly at the onset of mitosis and its reassembly after chromosome segregation. ANKLE2 dysfunction is associated with abnormal nuclear morphology and cell division. It regulates the nuclear envelope by mediating protein-protein interactions with barrier to autointegration factor (BANF1; also known as BAF) and with the kinase and phosphatase that modulate the phosphorylation state of BAF. In brain development, ANKLE2 is crucial for proper asymmetric division of neural progenitor cells. In humans, pathogenic loss-of-function mutations in ANKLE2 are associated with primary congenital microcephaly, a condition in which the brain is not properly developed at birth. ANKLE2 is also linked to other disease pathologies, including congenital Zika syndrome, cancer and tauopathy. Here, we review the molecular roles of ANKLE2 and the recent literature on human diseases caused by its dysfunction.

Fishburn AT, Florio CJ, Klaessens TN, Prince B, Adia NAB, Lopez NJ, Beesabathuni NS, Becker SS, Cherkashchenko L, Haggard Arcé ST, Hoang V, Shiu TN, Richardson RB, Evans MJ, Rückert C, Shah PS. Microcephaly protein ANKLE2 promotes Zika virus replication. mBio. 2025 Feb 5;16(2):e0268324. doi: 10.1128/mbio.02683-24. Epub 2025 Jan 13. PMID: 39804047; PMCID: PMC11796389.

Abstract

Orthoflaviviruses are positive-sense single-stranded RNA viruses that hijack host proteins to promote their own replication. Zika virus (ZIKV) is infamous among orthoflaviviruses for its association with severe congenital birth defects, notably microcephaly. We previously mapped ZIKV-host protein interactions and identified the interaction between ZIKV non-structural protein 4A (NS4A) and host microcephaly protein ankyrin repeat and LEM domain-containing 2 (ANKLE2). Using a fruit fly model, we showed that NS4A induced microcephaly in an ANKLE2-dependent manner. Here, we explore the role of ANKLE2 in ZIKV replication to understand the biological significance of the interaction from a viral perspective. We observe that ANKLE2 localization is drastically shifted to sites of NS4A accumulation during infection and that knockout of ANKLE2 reduces ZIKV replication in multiple human cell lines. This decrease in virus replication is coupled with a moderate increase in innate immune activation. Using microscopy, we observe dysregulated formation of virus-induced endoplasmic reticulum rearrangements in ANKLE2 knockout cells. Knockdown of the ANKLE2 ortholog in Aedes aegypti cells also decreases virus replication, suggesting ANKLE2 is a beneficial replication factor across hosts. Finally, we show that NS4A from four other orthoflaviviruses physically interacts with ANKLE2 and is also beneficial to their replication. Thus, ANKLE2 likely promotes orthoflavivirus replication by regulating membrane rearrangements that serve to accelerate viral genome replication and protect viral dsRNA from immune detection. Taken together with our previous results, our findings indicate that ZIKV and other orthoflaviviruses hijack ANKLE2 for a conserved role in replication, and this drives unique pathogenesis for ZIKV since ANKLE2 has essential roles in developing tissues.IMPORTANCEZIKV is a major concern due to its association with birth defects, including microcephaly. We previously identified a physical interaction between ZIKV NS4A and host microcephaly protein ANKLE2. Mutations in ANKLE2 cause congenital microcephaly, and NS4A induces microcephaly in an ANKLE2-dependent manner. Here, we establish the role of ANKLE2 in ZIKV replication. Depletion of ANKLE2 from cells significantly reduces ZIKV replication and disrupts virus-induced membrane rearrangements. ANKLE2's ability to promote ZIKV replication is conserved in mosquito cells and for other related mosquito-borne orthoflaviviruses. Our data point to an overall model in which ANKLE2 regulates virus-induced membrane rearrangements to accelerate orthoflavivirus replication and avoid immune detection. However, ANKLE2's unique role in ZIKV NS4A-induced microcephaly is a consequence of ZIKV infection of important developing tissues in which ANKLE2 has essential roles.

Shaheen R, Maddirevula S, Ewida N, Alsahli S, Abdel-Salam GMH, Zaki MS, Tala SA, Alhashem A, Softah A, Al-Owain M, Alazami AM, Abadel B, Patel N, Al-Sheddi T, Alomar R, Alobeid E, Ibrahim N, Hashem M, Abdulwahab F, Hamad M, Tabarki B, Alwadei AH, Alhazzani F, Bashiri FA, Kentab A, Şahintürk S, Sherr E, Fregeau B, Sogati S, Alshahwan SAM, Alkhalifi S, Alhumaidi Z, Temtamy S, Aglan M, Otaify G, Girisha KM, Tulbah M, Seidahmed MZ, Salih MA, Abouelhoda M, Momin AA, Saffar MA, Partlow JN, Arold ST, Faqeih E, Walsh C, Alkuraya FS. Genomic and phenotypic delineation of congenital microcephaly. Genet Med. 2019 Mar;21(3):545-552. doi: 10.1038/s41436-018-0140-3. Epub 2018 Sep 14. PMID: 30214071; PMCID: PMC6986385.

Abstract

Purpose: Congenital microcephaly (CM) is an important birth defect with long term neurological sequelae. We aimed to perform detailed phenotypic and genomic analysis of patients with Mendelian forms of CM.

Methods: Clinical phenotyping, targeted or exome sequencing, and autozygome analysis.

Results: We describe 150 patients (104 families) with 56 Mendelian forms of CM. Our data show little overlap with the genetic causes of postnatal microcephaly. We also show that a broad definition of primary microcephaly -as an autosomal recessive form of nonsyndromic CM with severe postnatal deceleration of occipitofrontal circumference-is highly sensitive but has a limited specificity. In addition, we expand the overlap between primary microcephaly and microcephalic primordial dwarfism both clinically (short stature in >52% of patients with primary microcephaly) and molecularly (e.g., we report the first instance of CEP135-related microcephalic primordial dwarfism). We expand the allelic and locus heterogeneity of CM by reporting 37 novel likely disease-causing variants in 27 disease genes, confirming the candidacy of ANKLE2, YARS, FRMD4A, and THG1L, and proposing the candidacy of BPTF, MAP1B, CCNH, and PPFIBP1.

Conclusion: Our study refines the phenotype of CM, expands its genetics heterogeneity, and informs the workup of children born with this developmental brain defect.

Naveed M, Kazmi SK, Amin M, Asif Z, Islam U, Shahid K, Tehreem S. Comprehensive review on the molecular genetics of autosomal recessive primary microcephaly (MCPH). Genet Res (Camb). 2018 Aug 8;100:e7. doi: 10.1017/S0016672318000046. PMID: 30086807; PMCID: PMC6865151.

Abstract

Primary microcephaly (MCPH) is an autosomal recessive sporadic neurodevelopmental ailment with a trivial head size characteristic that is below 3-4 standard deviations. MCPH is the smaller upshot of an architecturally normal brain; a significant decrease in size is seen in the cerebral cortex. At birth MCPH presents with non-progressive mental retardation, while secondary microcephaly (onset after birth) presents with and without other syndromic features. MCPH is a neurogenic mitotic syndrome nevertheless pretentious patients demonstrate normal neuronal migration, neuronal apoptosis and neural function. Eighteen MCPH loci (MCPH1-MCPH18) have been mapped to date from various populations around the world and contain the following genes: Microcephalin, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6, MFSD2A, ANKLE2, CIT and WDFY3, clarifying our understanding about the molecular basis of microcephaly genetic disorder. It has previously been reported that phenotype disease is caused by MCB gene mutations and the causes of this phenotype are disarrangement of positions and organization of chromosomes during the cell cycle as a result of mutated DNA, centriole duplication, neurogenesis, neuronal migration, microtubule dynamics, transcriptional control and the cell cycle checkpoint having some invisible centrosomal process that can manage the number of neurons that are produced by neuronal precursor cells. Furthermore, researchers inform us about the clinical management of families that are suffering from MCPH. Establishment of both molecular understanding and genetic advocating may help to decrease the rate of this ailment. This current review study examines newly identified genes along with previously identified genes involved in autosomal recessive MCPH.

103 year old neurologist

Howard Tucker has lived through a World War, the dawn of penicillin and the invention of the MRI—but nothing prepared him for TikTok fame at more than 100 years old. The centenarian doctor-turned-viral-sensation still lectures at Case Western Reserve University—offering both medical insights and life advice in equal doses.

Tucker turns 103 today—and he’s still not ready to fully retire.

Neurologist, Navy veteran, lawyer and part-time lecturer at the School of Medicine, Tucker holds the Guinness World Record as the world’s oldest practicing doctor. Though he stopped treating patients in 2022—he still remembers the exact date, Nov. 15—he remains an active medical educator and is always looking for new opportunities.

“It all fell into place easily,” Tucker said of his long career. “Just things I did as I went. One step at a time. As far as I’m concerned, I’ve lived a pedestrian life.”

Others would disagree. A World War II veteran, Tucker earned his medical degree in 1947 (The Ohio State University College of Medicine), served as chief neurologist for the U.S. Atlantic Fleet during the Korean War and then, after law school at Cleveland State University’s Cleveland–Marshall College of Law, passed the Ohio Bar exam at age 67. His mental acuity still sharp and witty, Tucker continues to consult on medicolegal cases and lecture students at Case Western Reserve, where his seven decades of medical knowledge still resonate.

In 2021, his grandson, Austin, and filmmaker, Taylor Taglianetti, began documenting Tucker’s life in a film called What’s Next?; the pair is currently booking screenings and seeking broader distribution. The documentary’s companion TikTok account—intended mostly to archive footage—took off, attracting more than 100,000 followers. The page has 4.8 million “likes.”

“People want to hear from someone who has truly lived,” Austin Tucker said. “He flips the idea of aging. There are a lot of older adults who want to contribute—and can.”

The project earned a Webby Award in 2025—and a few unforgettable memories, including spending time with Snoop Dogg backstage.

“Grandpa closed down the (Webby) afterparty with Questlove at 2 in the morning,” Austin Tucker said. “It’s hard to put into words how surreal this has all been.”

The digital fame may be new, but Tucker’s message isn’t: Stay curious. Stay engaged. Never stop learning.

Words of wisdom

The elder Tucker reminds his Case Western Reserve medical students not to rely too heavily on technology and to value the patient’s story above all.

“The invention of the CT scan changed everything,” he said, “but you still need to take a good history.”

Tucker credits his own longevity to a combination of genetics (his younger brother turns 100 later this year), regular exercise, curiosity, humor—and a refusal to hate.

“Hatred is devastating to the person who hates,” he said. “Pulse, heart rate, blood pressure all go up. Jealousy is also tremendously unhealthy; just accept yourself as who you are.”

Tucker used to swim a mile each day and jogged regularly; now, he uses a treadmill—the handrails offer security and balance. He occasionally snowshoes with family, including his wife, Sue, of 68 years.

Asked to share his philosophy on living healthy, he doesn’t miss a beat: “Irish playwright Bernard Shaw said the key to longevity is no liquor, no smoking, no caffeine and no red meat. Winston Churchill said he started his day with brandy, smoked between eight and 12 cigars per day and finished his day with red meat. I say—with absolute hubris—that I’m smarter than both of them. Moderation is everything.”

His advice to living a long, rewarding and productive life? “Don’t smoke. Don’t hate,” he said. “And don’t retire unless you absolutely have to; there’s still so much to learn. Why stop now?
https://case.edu/news/his-103rd-birthday-case-western-reserve-university-school-medicines-howard-tucker-has-no-plans-slow-down

EEG abnormalities correlated with developmental delay/intellectual disability in the absence of clinical seizures

Lee YJ, Jo YH, Choi SH, Yoo HW, Jo HY, Park SJ, Park KH, Kong JH, Lee YJ, Nam SO, Kim YM. Is Electroencephalography Useful in Children with Developmental Delays but without Overt Seizures?. Ann Child Neurol. 2024;32(2):105-114.

Abstract

Purpose
Electroencephalography (EEG) is useful for clarifying the association between cortical activity and cognitive processes in children. We investigated whether EEG abnormalities were correlated with developmental delay/intellectual disability (DD/ID) in the absence of clinical seizures.

Methods
We retrospectively identified 166 children with DD/ID who underwent EEG at Pusan National University Hospital between January 2011 and December 2021. We compared clinical characteristics and test results between those with normal and those with abnormal EEGs. Additionally, we analyzed EEG abnormalities in relation to neurodevelopmental disorders, specifically autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

Results
Of the 166 patients, 39 (23.5%) displayed abnormal EEGs, while 127 (76.5%) had normal EEGs. Of the former, 25 (64.1%) patients exhibited epileptiform discharges, including 22 (56.3%) with focal and three (7.7%) with generalized discharges. Focal discharges most frequently affected the central area (35.9%). Twenty patients (51.3%) exhibited rhythmic slowing patterns. Epilepsy diagnoses were significantly more common among patients with abnormal EEGs (n=8, 20.5%) than among those with normal EEGs (n=9, 7.1%) (P<0.001). Of 22 patients with ASD, five (12.8%) had abnormal EEGs. Of 13 patients with ADHD, five (36.4%) had abnormal EEGs, all with epileptiform discharges. Two patients with ASD and two with ADHD exhibited rhythmic slowing. Abnormal EEG findings were significantly more common among those with genetic abnormalities compared to genetically normal patients (26 vs. 13, P=0.017).

Conclusion
EEG represents a potential screening tool for children with DD. Abnormal EEG findings are associated with increased epilepsy risk, informing diagnosis and treatment planning.

I remain to be convinced.

Early phenotypic features of beta-propeller protein-associated neurodegeneration

Kim YS, Kim SY, Lee YJ, Oh SH, Choi SM, Lee JH. Early Phenotypic Features of Beta-Propeller Protein-Associated Neurodegeneration: Insights from a Korean Series. J Mov Disord. 2025 Dec 10. doi: 10.14802/jmd.25281. Epub ahead of print. PMID: 41367185.

Abstract

Beta-propeller protein-associated neurodegeneration (BPAN) is a rare X-linked disorder caused by pathogenic variants in WDR45 gene. Early diagnosis remains challenging due to nonspecific presentations in childhood. We report six pediatric patients with BPAN, identified through genetic testing performed during the evaluation of neurodevelopmental disorders. All were female and exhibited early developmental delay, severe language impairment, and varying degrees of motor dysfunction. Seizures occurred in four patients with varying severity. Two patients showed signs of central precocious puberty. Serum neuron-specific enolase was elevated in all tested patients. Brain MRI revealed corpus callosum thinning in all cases. Iron accumulation in the substantia nigra and globus pallidus was observed in only two older patients. WDR45 variants included two nonsense, two splice-site, one in-frame deletion, and one novel frameshift deletion. Our findings highlight early clinical features that may aid in recognizing BPAN prior to the emergence of distinctive MRI abnormalities or degenerative-phase manifestations.

Tuesday, December 9, 2025

Rabies from kidney transplant

A tragic series of events led to a fatal case of transplant-related rabies earlier this year.

Health officials announced Thursday that an organ recipient who underwent transplant surgery in Ohio died of rabies in February. Further investigation revealed that the donor had become infected with the fatal virus after saving a kitten from a skunk.

The unnamed patient, from Michigan, received the donor’s kidney in December 2024, and later developed severe symptoms that prompted hospitalization and "invasive" procedures, the Centers for Disease Control and Prevention (CDC) said.

He reportedly experienced fever, tremors, difficulty swallowing and fear of water and died 51 days after the transplant.

The CDC said the donor, whose donated tissue went to three other recipients, was infected with the silver-haired bat variant of rabies, suggesting the skunk had been infected by a bat.

Records revealed that the organ donor, from Idaho, was scratched on the shin while fending off a skunk that displayed "predatory aggression" six weeks before his death.

"In late October 2024, a skunk approached the donor as he held a kitten in an outbuilding on his rural property," the CDC said. "During an encounter that rendered the skunk unconscious, the donor sustained a shin scratch that bled, but he did not think he had been bitten. According to the family, the donor attributed the skunk’s behavior to predatory aggression toward the kitten."

In the following five weeks, the donor began experiencing hallucinations, trouble swallowing, difficulty walking and a stiff neck, the agency said.

Two days later, he was discovered unresponsive at home after a suspected heart attack, according to health officials. He was reportedly revived at a hospital but was declared brain-dead and removed from life support.

The CDC said his organs were donated after the family documented the skunk encounter in a donor risk assessment. However, health officials noted that the form did not screen for rabies, citing its "rarity in humans."

"In the United States, potential donors’ family members often provide information about a donor’s infectious disease risk factors, including animal exposures," the CDC said. "Rabies is excluded from routine donor pathogen testing because of its rarity in humans in the United States and the complexity of diagnostic testing. In this case, hospital staff members who treated the donor were initially unaware of the skunk scratch and attributed his pre-admission signs and symptoms to chronic comorbidities."

Health officials added that three other patients received corneal tissue from the same infected donor. They all underwent graft removal, received rabies treatment and remained asymptomatic, the CDC reported.

Health officials also reached out to 370 people who could have been in contact with the donor, according to the agency. Forty-six of them were recommended to undergo rabies procedures.

Health officials said the kidney recipient’s death marks the fourth documented case of rabies transmission through an organ transplant in the U.S. since 1978, emphasizing that the risk of such infections remains extremely low.

Transplant teams are now advised to consult public health officials if a potential donor has recent bites or scratches from rabies-susceptible animals, especially if the donor has had unexplained neurological symptoms.

However, "no standard guidance currently exists for addressing reported donor animal exposures by transplant teams," the CDC said.

About 1.4 million Americans receive care for possible rabies exposure annually, and fewer than 10 die from the disease due to effective prevention efforts, according to the agency.

Bonny Chu

https://www.foxnews.com/health/michigan-man-dies-rabies-after-receiving-kidney-from-infected-donor-who-saved-kitten-from-skunk-cdc

A Michigan resident has died of rabies after receiving an organ transplant.

The patient, who received the transplant at an Ohio hospital in December 2024, died of the fatal virus in January 2025, a spokesperson for the Michigan Department of Health and Human Services (MDHHS) confirmed to Fox News Digital.

"The person was a recent organ transplant recipient, and a public health investigation determined they contracted rabies through the transplanted organ," the spokesperson said.

The rabies confirmation was made by the CDC Rabies Laboratory.

The Michigan Department of Health and Human Services has worked closely with the Ohio Department of Health and the Centers for Disease Control and Prevention (CDC) on the investigation, the same source stated.

"Health officials worked together to ensure that people, including healthcare providers, who were in contact with the Michigan individual were assessed for possible exposure to rabies," the MDHHS stated. "Post-exposure preventive care, if appropriate, has been provided."

"There is no threat to the general public."

The organ donor was not a Michigan or Ohio resident, according to health officials. No additional information has been provided about the resident or the donor.

While organs are routinely screened for infectious diseases, cancers, quality and functionality prior to transplant, rabies testing is not typically performed.

"There is currently no country or institution that requires the screening of rabies among donors before organ transplantation surgery," according to information published by the National Institutes of Health.

In 2013, the CDC confirmed the death of four people in Maryland who contracted rabies after receiving organs from the same donor.

In 2004, the agency reported the rabies deaths of three people who received organs from a common infected donor.

What to know about rabies

Rabies is a deadly viral disease that is mainly transmitted to people and pets through bites or scratches from an infected animal, according to the CDC.

The virus affects the central nervous system, ultimately causing brain dysfunction. The infected person may experience anxiety, confusion, agitation and hallucinations, per the health agency.

Rabies is almost always fatal if the infected person does not receive medical attention before symptoms begin.

Around 60,000 people in the U.S. receive medical care after being exposed to rabies, the CDC stated.

Fewer than 10 deaths are reported in the country each year.

Most Americans who contract rabies are infected by bats.

Other animals that commonly carry rabies include raccoons, skunks and foxes.

Melissa Rudy

https://www.foxnews.com/health/patient-dies-rabies-organ-transplant-infected-donor

Features affecting treatment decisions and outcome in refractory status epilepticus

Damien C, Torcida Sedano N, Depondt C, Legros B, Gaspard N. Features affecting treatment decisions and outcome in refractory status epilepticus. Epilepsia. 2025 Aug;66(8):2779-2789. doi: 10.1111/epi.18423. Epub 2025 Apr 22. PMID: 40261726.

Abstract

Objective: Refractory status epilepticus (RSE) is associated with worse outcomes than responsive established status epilepticus (SE). Guidelines recommend that refractory convulsive SE should be treated with continuous intravenous anesthetic drugs (CIVADs). Many cases of nonconvulsive SE are not treated with CIVADs, and the use of anesthesia might be associated with increased mortality. The factors leading to the decision to use anesthesia and how these might affect outcome are still largely unknown. Our goal was to identify features of refractory SE associated with treatment choices and outcome. Methods: A single-center, retrospective study was conducted of all consecutive patients with RSE admitted to a tertiary center between January 2015 and December 2020. We collected demographic and clinical variables at SE onset and at time of third-line treatment, including ictal burden during the hour preceding the administration of the third-line treatment. The primary outcome measure was the decision to use CIVADs as third-line treatment. Secondary outcome measures were in-hospital mortality and functional outcome at discharge. Results: One hundred sixty-one RSE episodes were included. Of these, 29 (18%) received CIVADs as third-line treatment and 61 (38%) died. The type of third-line treatment was not associated with mortality. CIVADs were more likely to be used with higher ictal burden, fewer comorbidities, a lower Glasgow Coma Scale (GCS) score at time of third-line administration, and in the absence of history of epilepsy (odds ratio [OR] = 1.03, 0.76, .66, and .25, respectively). Multivariable analyses also identified comorbidities, an acute etiology, and lower GCS score at time of third-line administration as risk factors of mortality (OR = 1.43, .09, .28, and .80, respectively). Ictal burden was not associated with outcome. Significance: Ictal burden, semiology, and consciousness at time of third-line treatment are associated with the decision to use CIVADs in SE. Semiology and consciousness at time of third-line treatment are also associated with mortality.

Cervenka MC. The Refractory Status Epilepticus (RSE) is out of the Barn… the Current State of Refractory Status Epilepticus Management and Outcomes. Epilepsy Currents. 2025;0(0). doi:10.1177/15357597251406105

Commentary

Refractory status epilepticus (RSE), defined as status epilepticus that continues despite adequate doses of one first-line benzodiazepine and one appropriate second-line antiseizure medication, has a high risk of morbidity and mortality. Approaches vary between treating healthcare providers with regard to electroencephalogram (EEG) interpretation, threshold for, and comfort with starting sedating anesthetic medications to treat RSE.
Damien et al examined a retrospective review of a prospective database of 161 adults treated for RSE at Erasme Hospital from 2015 through 2020 to assess management strategies and clinical outcomes. They applied EEG and clinical criteria to quantify ictal burden, used the Charlson comorbidity index to measure comorbidity burden, and the Glasgow Coma Scale score to assess change in neurologic function over time. Status Epilepticus Severity Score (STESS), which includes a composite of level of consciousness, seizure type, age, and seizure history at the onset of status epilepticus, was also used to predict functional outcomes.
The authors found that intravenous anesthetic agents were used third-line in only 29 (18%) of patients, and the mortality rate was 38% overall. Patients with higher comorbidity burden, worse neurologic function at the time of RSE, acute onset, and no prior history of epilepsy were more likely to be treated with anesthetics as a third-line therapy. Nonconvulsive (NC) status epilepticus at onset, higher comorbidity burden, and absence of consciousness (lower modified Rankin scale score) at initiation of an intravenous anesthetic were all associated with poor outcome. Higher STESS was also associated with poor outcome, which helps validate the use of this tool for outcome prediction. Surprisingly, ictal burden at anesthesia initiation and progression to super-RSE (RSE that persists for 24 h or more despite aggressive management or returns after attempting to wean anesthetic agents) were not associated with worse outcome. In addition, when reviewing EEG findings prior to anesthesia initiation, 30% of patients treated did not meet the applied criteria for RSE in the 1 h prior to initiation.
The authors illustrated important study limitations, most notably its retrospective nature. This is particularly true when considering the latter finding that 30% of EEGs did not meet the criteria for RSE before anesthesia initiation. In a real-world scenario, the decision to start anesthetic agents may take place several hours before the initial dose is started, and therefore, evaluating based on only the 1 h immediately preceding initiation may not reflect the EEG findings at the time this decision was reached. Expert EEG interpretation has also been found to be highly subjective, with poor inter- and, at times, intra-rater reliability as well. These observations highlight the dynamic nature of the disease process and difficulty in determining the best time to escalate treatment. The finding that NC RSE was associated with worse outcome supports the need for rapid initiation of long-term, continuously monitored video EEG in order to immediately diagnose and treat this condition, and if unavailable, to immediately transfer a patient to a facility with these capabilities. Intermittent EEG monitoring could delay NC RSE discovery, appropriate treatment escalation, and result in worse outcomes and death.
A subset of patients in the study were conscious when anesthesia was administered, which is a challenging circumstance that healthcare providers, patients, and families can have a difficult time trying to navigate. For example, an asymptomatic patient with EEG findings meeting criteria for electrographic status epilepticus or a patient with epilepsia partialis continua (continuous electroclinical motor seizures with maintained consciousness) may be resistant to consider aggressive therapy. In these cases, the decision regarding whether or not individuals are started on anesthesia can be highly dependent upon the etiology, patient and family preferences, as well as the comfort and experience of the treating team with managing this condition. The optimal approach is unknown, and the study findings in this population may not be easily generalizable to other medical centers.
There are several notable limitations with regard to the study population described. The database from which patients were selected included nearly one year during the COVID-19 pandemic, a time which resulted in healthcare avoidance among patients, a reduction in healthcare resources, increased psychosocial stress, and higher non-COVID death rates overall. It would be interesting to investigate whether this impacted disease severity and comorbidities in patients with RSE, clinical practice in RSE management, and overall outcomes compared to the 5-year interval prior. Finally, individuals with post-anoxic RSE were excluded from the investigation. Studies have previously shown that there is a higher rate of morbidity and mortality in this patient population. However, outcomes may improve with aggressive management and therefore, inclusion of these patients in future studies is warranted.
Overall, the findings of this study support the need for robust long-term EEG monitoring resources to diagnose and treat RSE. The study provides an excellent road map for investigators designing clinical trials to treat RSE when making power calculations based on anticipated outcomes and identifying potential outcome measures to utilize. Innovative and evidence-based treatment strategies are needed to ultimately lead to reductions in morbidity and mortality based on the type and etiology of RSE, as well as patient comorbidities, tailored to the individual and circumstance.

Identifying the roles of decision-making and parental anxiety on medication adherence in pediatric epilepsy

Pathways Linking Parental Social Support and Decision-Making Participation to Medication Adherence in Children With Epilepsy: The Moderating Role of Parental Anxiety. Yang C, Huang R, Tao Q, Hao Z, Zhao L, Zhang L. Depress Anxiety. 2025 Sep 16;2025:7159579. doi: 10.1155/da/7159579. PMID: 40995429; PMCID: PMC12457068.

Abstract

Background: Medication adherence among pediatric epilepsy patients is frequently suboptimal, and the complex interplay between parental social support, decision-making participation, treatment satisfaction, and parental anxiety in influencing medication adherence remains underexplored. This study investigates both the direct and indirect pathways linking these factors to medication adherence and examines the mediating role of treatment satisfaction and the moderating role of parental anxiety. Methods: A cross-sectional study was conducted at three medical institutions between January 2020 and June 2024. Data on patient demographics and standardized scales measuring medication adherence, social support, communication and decision-making participation, treatment satisfaction, and parental anxiety were collected. Relationships among these variables were analyzed using structural equation modeling (SEM) and moderation analysis. Results: A total of 1056 patients were included in the study, with a mean age of 8.86 ± 3.99 years; 51.7% were male. Path analysis showed that parental social support (STD = 0.344, p < 0.001), communication and decision-making participation (STD = 0.392, p < 0.001), and treatment satisfaction (STD = 0.090, p < 0.05) had significant positive effects on medication adherence. Parental social support (STD = 0.483, p < 0.001) and communication and decision-making participation (STD = 0.203, p < 0.001) also strongly influenced treatment satisfaction. The indirect effects of social support and decision-making participation on medication adherence, mediated through treatment satisfaction, were statistically significant (p < 0.05). Parental anxiety, as a moderating factor, weakened the positive effects of social support, decision-making participation, and treatment satisfaction on medication adherence (p < 0.05). Conclusion: This study systematically develops an integrated model linking parental social support, communication and decision-making participation, treatment satisfaction, and anxiety to medication adherence in pediatric epilepsy. It highlights the mediating role of treatment satisfaction and the moderating role of parental anxiety. Enhancing parental social support and communication, improving treatment satisfaction, and addressing parental anxiety are key strategies to promote medication adherence.

Fine AL. Support is Critical: Identifying the Roles of Decision-Making and Parental Anxiety on Medication Adherence in Pediatric Epilepsy. Epilepsy Currents. 2025;0(0). doi:10.1177/15357597251406780

Commentary

Medication compliance can be challenging in any chronic pediatric disorder (and non-pediatric disorder) due to a variety of factors, such as challenging child behaviors, independence-seeking behaviors, communication barriers such as low medical literacy or provider communication issues, financial barriers, and others. When the potential consequences of medication noncompliance are breakthrough seizures and status epilepticus, increased hospitalizations, and increased mortality, the importance of medication compliance and reducing the barriers to adherence is dire. Social support can be characterized as the potential or perceived resources that are available or services being provided to an individual. Social support can vary depending on the circumstances (ie, such as caregiver vs patient role) and is typically a combination of resources which may include emotional support, enhanced education/information on the disease state, and practical/financial support.
Yang et al evaluated the impact of social support on communication and decision-making, treatment satisfaction, and caregiver anxiety and the effects on medication adherence in pediatric epilepsy. The authors performed a cross-sectional quantitative study of caregivers of children with epilepsy seen three healthcare facilities in China. The goal was to evaluate how the previously mentioned factors impact adherence, directly and indirectly, and the relationships between these factors by developing a hypothetical path model with medication adherence as the primary outcome variable. Path analysis is a form of multiple regression that entails creation of a path diagram evaluating the relationships between variables. The authors then used structural equation modeling (SEM) to allow for simultaneous analysis of the multiple mediating and moderating effects on medication adherence. The authors used a combination of self-designed scales, that is, Treatment Satisfaction Scale (SAT), Communication and Decision-Making Scale (CDMS), and Adherence to Medication scale (ADH), and available instruments, such as the Generalized Anxiety Disorder-7 (GAD-7) and Perceived Social Support Scale (PSSS).
The study included 1056 patients with a mean age of 8.86 years (sd = 3.99 years). Approximately half (50.5%) of the cohort was newly diagnosed with epilepsy and 98.5% of caregivers were parents. For those patients with established epilepsy, the minimum duration of epilepsy was 3 months per study inclusion criteria, with no information provided on the duration of epilepsy in included patients. Comorbidities were identified in 57.1% of patients (n = 603), including 22% with developmental delay and only a handful patients with ADHD (3.4%, 36 cases), intellectual disability (2.2%, 23 cases), depression or anxiety (0.4%, 4 cases), and autism (0.2%, 2 cases).
Based on scores from caregiver scales, 38.7% (n = 409) of patients exhibited poor treatment adherence, 12.9% (n = 36) of caregivers had low social support, 56.6% (n = 598) had moderate social support, and 30.5% (n = 322) had high social support. Medication adherence demonstrated a significantly positive correlation with satisfaction, social support, and communication/decision-making (p < 0.01 for all correlations). No significant correlation was found with caregiver anxiety (r = -0.058, p > 0.05), which the authors suggested indicated that indirect effects of anxiety were responsible for perceived effects.
Structural equation model analysis demonstrated that social support and communication and decision-making participation significantly improved medication adherence through direct and indirect pathways with direct positive effects seen for both. Satisfaction also significantly promoted medication adherence. Treatment satisfaction partially mediated the relationships between social support, communication and decision-making participation, and medication adherence via significant indirect effects of social support on satisfaction which enhanced medication adherence. Overall, total effects were positive on medication adherence. Caregiver anxiety was shown to significantly negatively moderate the relationships between social support, communication and decision-making participation, and treatment satisfaction and weakened the positive effects of these on medication adherence (Figure 1). Overall, these results demonstrated clear relationships between these factors, with total positive effects of caregiver support, communication and decision-making participation, and treatment satisfaction on medication adherence, while caregiver anxiety negatively impacts these relationships, potentially contributing to reduced medication adherence.



Figure 1. Path relationship results: Solid lines represent significant relationships on path analysis and significant direct effects of perceived social support, communication decision making, and satisfaction on medication adherence. Dashed lines represent significant indirect effects and mediating effects of parental support and communication and decision making on satisfaction with indirect effects on satisfaction positively impacting medication adherence. Dotted lines represent moderating effects of parental anxiety, with “X” representing negative effects, on the relationships between social support, communication decision making, and satisfaction on medication adherence.

The study findings, while not surprising, are important. The personal experience of caregivers of children with chronic medical conditions is impacted by numerous factors including social support, disease burden, medical barriers, caregivers’ coping abilities.7 Given the potential complexity of an individual's epilepsy journey, it is not unexpected that enhancing social support of caregivers improves the overall experience. Qualitative studies have previously identified that for caregiver decision-making in epilepsy important factors include being informed and knowledgeable about epilepsy and therapies, a sense of responsibility, emotional and social support, personal beliefs, and resources.
Some considerations of the study by Yang et al would be the generalizability of the findings to other populations, as there could be cultural and location-specific factors which contributed to their findings. Part of social support can include resources and financial support, which was not really explored in this study. If there are additional stressors due to a lack of financial resources, this could also contribute to increased anxiety and thus weaken the effects seen on medication adherence. It would have been interesting if the authors explored if there were common factors among the patients with the lowest level of social support, which only made up a minority of the caregivers of the included patients.
The authors included patients with a previous diagnosis of epilepsy as well as new onset epilepsy, however as previously noted, the minimum required length of epilepsy history was 3 months, which is still quite early in the potential disease course. One big question is how can these results be applied to patients with severe epilepsies and numerous comorbidities? This study excluded patients who had severe cognitive or developmental concerns including autism, cerebral palsy, or intellectual disability, as well as those with other chronic medical conditions. That would indicate that this study did not really include patients with intractable epilepsy, at least not based on what is reported. This would certainly impact the study findings given that patients with refractory epilepsy likely have more medical complexity and needs, which further could increase caregiver anxiety and an increased need for social support. The rates of comorbidities seen in this cohort was 57.1%, and rates of comorbidities were lower than may be expected, particularly for patients with comorbid ADHD, depression, anxiety, and autism based on prior literature.9 This may skew the sample towards a population that is less impacted by comorbidities and thus could alter generalizability of the study.
This question remains regarding differences between patient and caregiver populations in children with well-controlled epilepsy and in children with refractory epilepsy and developmental and epileptic encephalopathies. Is there better medication adherence with increased medical complexity, or is there an increased impact of social support on medication adherence in a more severely affected population? Future studies could potentially use similar modeling to assess the impact of social support on caregivers of children with intractable epilepsy and treatment adherence. Regardless, this study highlights the importance of assessing support for families and identifying care gaps in order to optimize adherence to therapies for children with epilepsy.















Monday, December 8, 2025

Chromosome 17p13.3 microdeletions

Inspired by a patient

Ji X, Xu Q, Lu Y, Liu B, Xiao F, Ni Q, Xu S, Liu R, Li G, Wu B, Zhou S, Wang H. Deep clinical and genetic analysis of 17p13.3 region: 38 pediatric patients diagnosed using next-generation sequencing and literature review. BMC Med Genomics. 2025 May 19;18(1):90. doi: 10.1186/s12920-025-02155-y. PMID: 40390087; PMCID: PMC12090631.

Abstract

Background: Chromosome 17p13.3 is a region of genomic instability associated with different neurodevelopmental diseases. The malformation spectrum of 17p13.3 microdeletions ranges from an isolated lissencephaly sequence to Miller-Dieker syndrome, while 17p13.3 microduplications result in autism, learning disabilities, microcephaly and other brain malformations. This study aims to provide a more comprehensive delineation of the clinical and genetic characteristics associated with 17p13.3 alterations.

Methods: We retrospectively analyzed the next-generation sequencing (NGS) data of more than 40 thousand patients from January 2016 to December 2021 and identified 38 pediatric patients with copy-number variations (CNVs) or single-nucleotide variations (SNVs) in 17p13.3 region. Published patients with CNVs in the 17p13.3 region were also collected and we performed a Chi-square test to compare the phenotype spectrum of microdeletions and microduplications.

Results: Among the 27 CNV patients, 20 patients with microdeletions and 7 patients with microduplications were found. PAFAH1B1 was the most frequently deleted gene and CRK was the most frequently duplicated gene. Affected genes in 11 SNV patients included PAFAH1B1 and PRPF8. Developmental delay was the most common abnormality detected in the 38 patients (29/38, 76.3%). Of note, Case 10 presented omphalocele and Case 23 presented scoliosis, webbed neck and bone cyst, all of which were unusual variant phenotypes in this region. The Chi-square test revealed that epilepsy, lissencephaly and short stature were statistically significant with microdeletions, while behavioral abnormalities and hand and foot abnormalities were significant with microduplications (p < 0.01).

Conclusions: While PAFAH1B1, YWHAE and CRK are associated with major phenotypes of 17p13.3, RTN4RL1 may be involved in white matter changes and HIC1 might contribute to the occurrence of omphalocele. This study provided a comprehensive understanding of genetic information and phenotype spectrum of the 17p13.3 region.

Emrick LT, Rosenfeld JA, Lalani SR, Jain M, Desai NK, Larson A, Kripps K, Vanderver A, Taft RJ, Bluske K, Perry D, Nagakura H, Immken LL, Burrage LC, Bacino CA, Belmont JW, Network UD, Lee B. Microdeletions excluding YWHAE and PAFAH1B1 cause a unique leukoencephalopathy: further delineation of the 17p13.3 microdeletion spectrum. Genet Med. 2019 Jul;21(7):1652-1656. doi: 10.1038/s41436-018-0358-0. Epub 2018 Dec 20. PMID: 30568308; PMCID: PMC6586530.

Abstract

Purpose: Brain malformations caused by 17p13.3 deletions include lissencephaly with deletions of the larger Miller-Dieker syndrome region or smaller deletions of only PAFAH1B1, white matter changes, and a distinct syndrome due to deletions including YWHAE and CRK but sparing PAFAH1B1. We sought to understand the significance of 17p13.3 deletions between the YWHAE/CRK and PAFAH1B1 loci.

Methods: We analyzed the clinical features of six individuals from five families with 17p13.3 deletions between and not including YWHAE/CRK and PAFAH1B1 identified among individuals undergoing clinical chromosomal microarray testing or research genome sequencing.

Results: Five individuals from four families had multifocal white matter lesions while a sixth had a normal magnetic resonance image. A combination of our individuals and a review of those in the literature with white matter changes and deletions in this chromosomal region narrows the overlapping region for this brain phenotype to ~345 kb, including 11 RefSeq genes, with RTN4RL1 haploinsufficiency as the best candidate for causing this phenotype.

Conclusion: While previous literature has hypothesized dysmorphic features and white matter changes related to YWHAE, our cohort contributes evidence to the presence of additional genetic changes within 17p13.3 required for proper brain development.

Barros Fontes MI, Dos Santos AP, Rossi Torres F, Lopes-Cendes I, Cendes F, Appenzeller S, Kawasaki de Araujo T, Lopes Monlleó I, Gil-da-Silva-Lopes VL. 17p13.3 Microdeletion: Insights on Genotype-Phenotype Correlation. Mol Syndromol. 2017 Jan;8(1):36-41. doi: 10.1159/000452753. Epub 2016 Nov 25. PMID: 28232781; PMCID: PMC5260540.

Abstract

Microdeletions in the chromosomal region 17p13.3 are associated with neuronal migration disorders, and PAFAB1H1 is the main gene involved. The largest genomic imbalances, including the YWHAE and CRK genes, cause more severe structural abnormalities of the brain and other associated dysmorphic features. Here, we describe a 3-year-old boy with a microdeletion in 17p13.3 presenting with minor facial dysmorphisms, a cleft palate, neurodevelopmental delay, and behavioral disorder with no structural malformation of the brain. The patient was evaluated by a clinician using a standard protocol. Laboratory investigation included GTG-banding, whole-genome AGH, and array-CGH. Whole-genome AGH and array-CGH analysis identified an estimated 2.1-Mb deletion in the 17p13.3 region showing haploinsufficiency of the YWHAE, CRK, H1C1, and OVCA1 genes and no deletion of PAFAH1B1. The complex gene interaction on brain development and function is illustrated in the genotype-phenotype correlation described here. This report reinforces the importance of the 17p13.3 region in developmental abnormalities and highlights the weak implication of the HIC1 and OVCA1 genes in palatogenesis.

Blazejewski SM, Bennison SA, Smith TH, Toyo-Oka K. Neurodevelopmental Genetic Diseases Associated With Microdeletions and Microduplications of Chromosome 17p13.3. Front Genet. 2018 Mar 23;9:80. doi: 10.3389/fgene.2018.00080. PMID: 29628935; PMCID: PMC5876250.

Abstract

Chromosome 17p13.3 is a region of genomic instability that is linked to different rare neurodevelopmental genetic diseases, depending on whether a deletion or duplication of the region has occurred. Chromosome microdeletions within 17p13.3 can result in either isolated lissencephaly sequence (ILS) or Miller-Dieker syndrome (MDS). Both conditions are associated with a smooth cerebral cortex, or lissencephaly, which leads to developmental delay, intellectual disability, and seizures. However, patients with MDS have larger deletions than patients with ILS, resulting in additional symptoms such as poor muscle tone, congenital anomalies, abnormal spasticity, and craniofacial dysmorphisms. In contrast to microdeletions in 17p13.3, recent studies have attracted considerable attention to a condition known as a 17p13.3 microduplication syndrome. Depending on the genes involved in their microduplication, patients with 17p13.3 microduplication syndrome may be categorized into either class I or class II. Individuals in class I have microduplications of the YWHAE gene encoding 14-3-3ε, as well as other genes in the region. However, the PAFAH1B1 gene encoding LIS1 is never duplicated in these patients. Class I microduplications generally result in learning disabilities, autism, and developmental delays, among other disorders. Individuals in class II always have microduplications of the PAFAH1B1 gene, which may include YWHAE and other genetic microduplications. Class II microduplications generally result in smaller body size, developmental delays, microcephaly, and other brain malformations. Here, we review the phenotypes associated with copy number variations (CNVs) of chromosome 17p13.3 and detail their developmental connection to particular microdeletions or microduplications. We also focus on existing single and double knockout mouse models that have been used to study human phenotypes, since the highly limited number of patients makes a study of these conditions difficult in humans. These models are also crucial for the study of brain development at a mechanistic level since this cannot be accomplished in humans. Finally, we emphasize the usefulness of the CRISPR/Cas9 system and next generation sequencing in the study of neurodevelopmental diseases.

Monday, December 1, 2025

GLRA1 hyperekplexia

Inspired by a patient

Ferraroli E, Perulli M, Veredice C, Contaldo I, Quintiliani M, Ricci M, Venezia I, Citrigno L, Qualtieri A, Spadafora P, Cavalcanti F, Battaglia DI. Hereditary Hyperekplexia: A New Family and aSystematic Review of GLRA1 Gene-Related Phenotypes. Pediatr Neurol. 2022 Jul;132:45-49. doi: 10.1016/j.pediatrneurol.2022.05.002. Epub 2022 May 17. PMID: 35636282.

Abstract

Hereditary hyperekplexia (HPX) is a genetic neurodevelopmental disorder recently defined by the triad of (1) neonatal hypertonia, (2) excessive startle reflexes, and (3) generalized stiffness following the startle. Defects in GLRA1 are the most common cause of HPX, inherited both in an autosomal dominant and autosomal recessive manner. GLRA1 mutations can also cause milder phenotypes in the startle syndromes spectrum, but the prevalence is uncertain and no clear genotype-phenotype correlation has emerged yet. Moreover, the prevalence of neurodevelopmental outcomes has not been clearly defined. Here we report a new family of patients with a typical HPX phenotype, linked to a novel GLRA1 mutation, inherited with a recessive pattern. We then perform a systematic review of the literature of GLRA1-related HPX, describing the main epidemiological features of 210 patients. We found that GLRA1-related phenotypes do not necessarily fulfill the current criteria for HPX, including also milder and later-onset phenotypes. Among clinical features of the disease, neurodevelopmental issues were reported in a third of the sample; interestingly, we found that these problems, particularly when severe, were more common in homozygous than in heterozygous patients. Additional clinical and preclinical studies are needed to define predictors of adverse neurodevelopmental outcomes and underlying mechanisms.

Thomas RH, Drew CJ, Wood SE, Hammond CL, Chung SK, Rees MI. Ethnicity can predict GLRA1 genotypes in hyperekplexia. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):341-3. doi: 10.1136/jnnp-2014-307903. Epub 2014 Jun 26. PMID: 24970905.

Abstract

Objectives: Hyperekplexia is predominantly caused by mutations in the α-1 subunit of the inhibitory glycine receptor (GLRA1). Three quarters of cases show autosomal-recessive inheritance.

Methods: We carefully ascertained reports of ethnicity from our hyperekplexia research cohort. These were compared with all published cases of hyperekplexia with an identified genetic cause. Ethnicities were subgrouped as Caucasian, Asian, Arabic, Turkish, Jewish or Afro-American.

Results: We report the ethnicity of 90 cases: 56 cases from our service augmented by 34 cases from the literature. Homozygous deletions of exons 1 to 7 are predominantly seen in people with Turkish backgrounds (n=16/17, p<0.001). In contrast, the dominant point mutation R271 is seen in people of Asian, Caucasian and African-American heritage (n=19) but not in people with Arab or Turkish ethnicities (p<0.001).

Conclusions: Self-declared ethnicity can predict gene-screening outcomes. Cultural practices influence the inheritance patterns and a Caucasian founder is postulated for R271 mutations.

Chung SK, Vanbellinghen JF, Mullins JG, Robinson A, Hantke J, Hammond CL, Gilbert DF, Freilinger M, Ryan M, Kruer MC, Masri A, Gurses C, Ferrie C, Harvey K, Shiang R, Christodoulou J, Andermann F, Andermann E, Thomas RH, Harvey RJ, Lynch JW, Rees MI. Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci. 2010 Jul 14;30(28):9612-20. doi: 10.1523/JNEUROSCI.1763-10.2010. PMID: 20631190; PMCID: PMC6632444.

Abstract

Hyperekplexia is a rare, but potentially fatal, neuromotor disorder characterized by exaggerated startle reflexes and hypertonia in response to sudden, unexpected auditory or tactile stimuli. This disorder is primarily caused by inherited mutations in the genes encoding the glycine receptor (GlyR) alpha1 subunit (GLRA1) and the presynaptic glycine transporter GlyT2 (SLC6A5). In this study, systematic DNA sequencing of GLRA1 in 88 new unrelated human hyperekplexia patients revealed 19 sequence variants in 30 index cases, of which 21 cases were inherited in recessive or compound heterozygote modes. This indicates that recessive hyperekplexia is far more prevalent than previous estimates. From the 19 GLRA1 sequence variants, we have investigated the functional effects of 11 novel and 2 recurrent mutations. The expression levels and functional properties of these hyperekplexia mutants were analyzed using a high-content imaging system and patch-clamp electrophysiology. When expressed in HEK293 cells, either as homomeric alpha1 or heteromeric alpha1beta GlyRs, subcellular localization defects were the major mechanism underlying recessive mutations. However, mutants without trafficking defects typically showed alterations in the glycine sensitivity suggestive of disrupted receptor function. This study also reports the first hyperekplexia mutation associated with a GlyR leak conductance, suggesting tonic channel opening as a new mechanism in neuronal ligand-gated ion channels.

Elmslie FV, Hutchings SM, Spencer V, Curtis A, Covanis T, Gardiner RM, Rees M. Analysis of GLRA1 in hereditary and sporadic hyperekplexia: a novel mutation in a family cosegregating for hyperekplexia and spastic paraparesis. J Med Genet. 1996 May;33(5):435-6. doi: 10.1136/jmg.33.5.435. PMID: 8733061; PMCID: PMC1050620.

Abstract

Hyperekplexia is a rare condition characterised by the presence of neonatal hypertonia and an exaggerated startle response. Mutations have been described in GLRA1, the gene encoding the alpha 1 subunit of the glycine receptor, in dominant families with hyperekplexia and in a single sporadic case, thought to represent an autosomal recessive form of the disease. In this study the coding region of the GLRA1 was analysed in eight probands with hyperekplexia by restriction digest and sequencing. Two familial cases were found to possess the previously described G1192A (R271Q) mutation in exon 6. In an additional family in which hyperekplexia cosegregates with spastic paraparesis, a novel A to G transversion at nucleotide 1206 in exon 6 was detected that changes a lysine at amino acid 276 to a glutamate (K276E). In four sporadic cases no mutations were found. In addition, one familial case did not have a mutation in the coding region of the gene.

Idiopathic intracranial hypertension without papilledema

Inspired by a colleague

Beri S, Gosalakkal JA, Hussain N, Balky AP, Parepalli S. Idiopathic intracranial hypertension without papilledema. Pediatr Neurol. 2010 Jan;42(1):56-8. doi: 10.1016/j.pediatrneurol.2009.07.021. PMID: 20004864.
\
Abstract

Idiopathic intracranial hypertension is characterized by high cerebrospinal fluid pressure with no underlying structural or systemic cause. Idiopathic intracranial hypertension without papilledema, although well-described in adults, is rarely reported in the pediatric population. The usual presentation is similar to that of chronic daily headache, with some features of migraine. However, treatment modalities are different, and specific therapy can lead to significant improvement in symptoms. We describe six children with chronic daily headache, who were diagnosed with idiopathic intracranial hypertension without papilledema. The response to medical management was variable. One child required a lumboperitoneal shunt for persistent signs, with good surgical outcome.

Favoni V, Pierangeli G, Toni F, Cirillo L, La Morgia C, Abu-Rumeileh S, Messia M, Agati R, Cortelli P, Cevoli S. Idiopathic Intracranial Hypertension Without Papilledema (IIHWOP) in Chronic Refractory Headache. Front Neurol. 2018 Jun 26;9:503. doi: 10.3389/fneur.2018.00503. PMID: 29997572; PMCID: PMC6029151.

Abstract

Background: To determine the prevalence of Idiopathic intracranial hypertension without papilledema (IIHWOP) testing revised diagnostic criteria by Friedman in refractory chronic headache (CH) patients.

Methods: This is a prospective observational study. Each patient underwent ophthalmologic evaluation and Optical Coherence Tomography; brain magnetic resonance venography (MRV) and a lumbar puncture (LP) with opening pressure (OP) measurement. CSF withdrawal was performed in patients with CSF OP > 200 mmH20. IIHWOP was defined according Friedman's diagnostic criteria. Effect of CSF withdrawal was evaluated clinically in a 6-month follow-up and with a MRV study at 1 month.

Results: Forty-five consecutive patients were enrolled. Five were excluded due to protocol violations. Analyses were conducted in 40 patients (32 F, 8 M; mean age 49.4 ± 10.8). None had papilledema. Nine patients (22.5%) had OP greater than 200 mmH2O, two of them above 250 mmH2O. Two (5%) had neuroimaging findings suggestive of elevated intracranial pressure. One of them (2.5%) met the newly proposed diagnostic criteria by Friedman for IIHWOP. After CSF withdrawal seven (77.8%) of the nine patients improved. No changes in neuroimaging findings were found.

Conclusions: We found a low prevalence (2.5%) of IIHWOP in refractory CH patients according to current diagnostic criteria. In agreement with Friedman's criteria, our results confirm that a diagnosis of IIHWOP should be based on CSF OP and the combination of neuroradiological findings. However, where to set the CSF OP upper limit in IIHWOP needs further field testing. Although IIHWOP is a rare clinical condition, it should be considered and treated in refractory CH patients.

Sunday, November 23, 2025

Neurelis apology

 



Lexidrug tells me the price is $439.12 for each dose, or $2,195.60 for a 5 pack. Fortunately, the shelf life is 32-36 months. Given that most of my patients will never actually use a rescue medication, that is a hefty price.

Concentrate (diazePAM Oral) 5 mg/mL (per mL): $5.00

Cheap Diazepam Intensol (5 mg/mL) has been utilized extensively as a rescue medication for seizures, generally given buccally. I have not yet seen evidence for the superiority of Valtoco vs Diazepam Intensol.

Midazolam 10 mg/2 ml (per ml)  $0.75 - $3.86

Cheap midazolam has been used extensively as an intranasal or buccal rescue medication for seizures.

Nayzilam per 5 mg $400.15

From Nickels, Katherine C. “Less Effective and More Expensive: Is It Time to Move on From Rectal Diazepam?.” Epilepsy currents vol. 18,1 (2018): 27-28. doi:10.5698/1535-7597.18.1.27: According to this study, the most cost-effective therapy was buccal midazolam, with absolute cost effectiveness of $7.93/SS. Nasal midazolam, nasal lorazepam, and intramuscular midazolam had similar costs, ranging from $13.37/SS to $15.54/SS. The only outlier was rectal diazepam, costing $435.16/SS at the time of their study. Rectal diazepam remained the outlier when incremental effectiveness and willingness to pay were analyzed. The authors determined that, based on efficacy, rectal diazepam would not be cost-effective unless the cost were $6 or less. The current cost of rectal diazepam is approximately $326.

Valtoco and Nayzilam are the current outliers.

I am currently freely prescribing Valtoco and Nayzilam, but I hold my nose when I do so.

Saturday, November 22, 2025

Do classic psychedelics increase the risk of seizures?

Courtesy of a colleague

Soto-Angona Ó, Fortea A, Fortea L, Martínez-Ramírez M, Santamarina E, López FJG, Knudsen GM, Ona G. Do classic psychedelics increase the risk of seizures? A scoping review. Eur Neuropsychopharmacol. 2024 Aug;85:35-42. doi: 10.1016/j.euroneuro.2024.05.002. Epub 2024 Jun 24. PMID: 38917636.

Abstract

Seizures are a concerning adverse event frequently associated with the use of psychedelics, and hence, studies involving these substances tend to exclude patients with past history of epilepsy. This is especially relevant because epileptic seizures are markedly increased in the population suffering from mental disorders, and psychedelic assisted therapy is being researched as a promising treatment for several of them. To determine the extent of the current literature on the relationship between classic psychedelics and seizures, a scoping review was performed using the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). The search was conducted in PubMed, Web of Science, Google scholar, LILACS and Scielo, and both animal and human models were included. A total of 16 publications on humans, and 11 on animals, were found. The results are heterogeneous, but globally suggest that psychedelics may not increase the risk of seizures in healthy individuals or animals in the absence of other drugs. However, concomitant use of other substances or drugs, such as kambo or lithium, could increase the risk of seizures. Additionally, these conclusions are drawn from data lacking sufficient external validity, so they should be interpreted with caution. Future paths for research and a summary on possible neurobiological underpinnings that might clarify the relationship between classical psychedelics and seizures are also provided.

Thursday, November 20, 2025

Autoimmune autonomic ganglionopathy

An Australian woman has decided to end her life with medical assistance to “die on her own terms” after years of living with a rare and terminal neurological disease.

Annaliese Holland, 25, said she has been ill since she was a child, enduring repeated hospital stays as doctors tried to diagnose an illness that caused chronic pain, nausea and vomiting — and forced her to depend on IV feeding for the past decade, she told News.com.au.

She was diagnosed with autoimmune autonomic ganglionopathy, a rare autoimmune disease in which the body attacks the autonomic ganglia, the nerves responsible for controlling involuntary bodily functions, according to the Cleveland Clinic.

Years before her diagnosis, Holland’s bowels acted as if they were blocked, despite there actually being nothing stopping them.

Feeding tubes proved ineffective as she continued vomiting, and once doctors realized her stomach wasn’t emptying, they placed her on total parenteral nutrition, which supplies nutrients through an IV to bypass digestion.

“Because of the line straight into your bloodstream, if you get an infection, it turns to sepsis really quickly, which is very, very dangerous,” Holland said, adding that she has survived sepsis — a life-threatening reaction in which the body’s response to an infection damages its own tissues and organs — 25 times.

After doctors spent the majority of her young life trying to pinpoint what illness had been plaguing her, it wouldn’t be until Holland turned 18 and was transferred to an adult hospital that she would get an answer.

Holland said she had been told her condition was terminal when she turned 22.

Holland’s medications have weakened her bones to the point of severe osteoporosis, leaving her in constant pain and resulting in four spinal fractures, a fractured sternum, and nearly catastrophic pressure on her heart and lungs.

“I was so miserable,” Holland said. “You can’t change it so you have to just deal with it really. Even though there’s beautiful moments in my days, they are exhausting and long. I’m in chronic debilitating pain.”

Her illness has left her watching life race by from a hospital room, where she spent her 18th and 21st birthdays, as her friends now marry and start families.

“Everyone’s life is moving and I’m just stuck. I’m not living. I’m surviving every day, which is tough,” she said, noting that her disease feels like “walking on a field of landmines.”

“No man wants to date someone dying, I get it.”

Knowing that her life will end, the 25-year-old said she has decided to “die on my own terms” with voluntary assisted dying (VAD) — a legal option in Australia that provides terminally ill patients with self-administered life-ending medication.

She has watched life race ahead from her hospital room — where she spent her 18th and 21st birthdays — while her friends move on to marriages and families.

“Life for me now is getting up each day doing what I need to do medically, taking the painkillers, trying to get through the day, just to go to bed and do it all again,” she said.

“I have the most incredible team of doctors and nurses who have watched what I have been through and I told them I don’t want this anymore.”

While Holland appears at peace with the decision, her parents and sister are shattered by the idea.

“I remember talking to my dad in the kitchen one night and I said, ‘Dad, I’ve had enough.’ And he went, ‘So you’re giving up?’” she said.

She said the turning point for her father, Patrick, came when she was revived by doctors in the hospital and pleaded, “Dad, please let me go. I won’t hate you if you do.”

“I said, ‘If this happens again, I don’t want anything. And please know that in my heart, you letting me go and saying no to treatment … I’m happy with and that’s what I want,’” Holland said, fighting back tears.

“He turned to me and goes, ‘I don’t know how you do it and I totally understand that you’ve had enough.’”

Holland’s mom, Armanda, said she still hopes for a miracle, though she “realistically understands the challenges” her daughter faces.

Knowing that her life will end, the 25-year-old said she has decided to “die on my own terms” with voluntary assisted dying — a legal option in Australia that provides terminally ill patients with self-administered life-ending medication.

Following a three-week evaluation process, Holland was approved for VAD.

“I think it’s so weird to be happy, but I was so happy when I found out I was approved, I was crying,” she recalled.

“It’s hard because for me I am in pain and then I am at peace, but then I put the pain onto my family. You have this battle in your head of not wanting to hurt them so I will put some thought into how it will happen.”

Holland added that she’s “lucky that I do have this choice.”

“It’s one of the bravest things you could ever do, to say I want VAD. It’s not giving up. You’ve had enough and you fought bloody hard.”

Richard Pollina

https://nypost.com/2025/11/20/world-news/terminally-ill-australian-woman-annaliese-holland-to-die-on-own-terms-after-battling-rare-neurological-disease-her-entire-life/




Wednesday, November 19, 2025

Clinical, radiologic, and pathologic associations of executive dysfunction in children with focal cortical dysplasia–related epilepsy

Clinical, Radiologic, and Pathologic Associations of Executive Dysfunction in Children With Focal Cortical Dysplasia–Related Epilepsy. Nathan T. Cohen , Hua Xie, Venkata Sita Priyanka Illapani, Sonya M. Leikin, Xiaotong Li, Ana Moreno Chaza,,Chloe Hooker, L. Gilbert Vezina, Chima O. Oluigbo, Hayley J. Loblein, William D. Gaillard, Hayley J. Loblein, William D. Gaillard, Leigh N. Sepeta, and Madison M. Berl. Neurology. December 9, 2025 issue 105 (11) e214352 https://doi.org/10.1212/WNL.0000000000214352

Abstract

Background and Objective
Executive dysfunction (ExD) is a common comorbidity of focal epilepsy. Focal cortical dysplasia (FCD) is the most common lesional cause of epilepsy in children. We aimed to investigate clinical, etiologic (pathology), and anatomic vs functional network associations with ExD in FCD-related epilepsy. FCD lesion-network interactions may underlie ExD. The primary analysis was to evaluate whether FCD colocalization to frontoparietal control network or attention networks is associated with ExD. We also evaluated whether FCD type I pathology is associated with ExD because it is reported to be associated with worse intellectual function.

Methods
Patients with FCD were included from retrospective surgical/radiologic databases at Children's National Hospital from January 2000 to January 2022 if they had preoperative neuropsychological testing. FCD colocalization to the Yeo 7-network atlas was determined. Clinical, radiologic, and pathologic factors were evaluated for association with ExD. The primary outcome measure was ExD measured categorically (ExD/Not ExD) and linearly (Behavior Rating Inventory of Executive Function [BRIEF]-Global Executive Composite [GEC] T-score).

Results
Ninety-three patients with FCD (45% female) had preoperative BRIEF-GEC T-scores sampled at 11.4 years (SD 4.5 years). Control network colocalization (odds ratio [OR] 3.6, 95% CI 0.94–13.9, p < 0.05) and FCD type I (OR 4.45, 95% CI 1.39–14.3, p = 0.009) are associated with ExD (BRIEF-GEC T-score ≥65). Control network colocalization is associated with Cognitive Regulation Index (mean difference 8.3, 95% CI 0.7–15.9, p = 0.03) and Plan/Organize subscale (8.4, 95% CI 0.9–16.0, p = 0.028). FCD type I is associated with BRIEF-GEC T-score (8.3, 95% CI 2.3–14.2, p = 0.007), Cognitive Regulation Index (7.1, 95% CI 1.2–13.1, p = 0.019), Working Memory (7.4, 95% CI 1.2–13.6, p = 0.021), Plan/Organize (6.0, 95% CI 0.21–11.8, p = 0.042), Shift (8.1, 95% CI 1.6–14.7, p = 0.015), and Emotional Control (8.5, 95% CI 2.5–14.5, p = 0.006) subscales. These findings were not related to Full Scale IQ. FCD colocalization to attentional network (dorsal or ventral), lobar location, or age seizure onset was not associated with ExD.

Discussion
These data demonstrate the importance of lesion-network interaction in neuropsychological comorbidity (ExD) in focal epilepsy, unrelated to lesion size or lobar location. FCD colocalization to the Frontoparietal Control network is associated with ExD in a heterogeneous cohort of FCD-related epilepsy. A network-level structure-function correlation is suggested as the most affected processes of cognitive regulation (e.g., planning/organization) are domains regulated by this network. This work contributes toward a more unified theory of focal epilepsy, by beginning to explain common neuropsychological deficits seen across the epilepsies by cortical lesion-network interaction and regardless of lobar location.

Laryngeal cleft

A terrified Long Island mom’s quick-thinking but devastatingly painful choice helped save the life of her toddler son over the summer — and eventually revealed the exceptionally rare condition he suffers from.

“Picture breathing through a milkshake straw, then breathing through a regular straw, then trying to breathe through a coffee straw,” Maria Carlin, 36, recently told The Post of her 4-year-old Jack’s harrowing experience in late July.

“We got to a point where I said to myself, ‘It doesn’t get higher-pitched. … I know what comes next.’ [His breathing] just stopped.”

Carlin, a nurse at North Shore University Hospital, got her stricken son — who was previously undiagnosed — into the car and began driving to the medical facility after he had spent the night crying in agony without “a single symptom of anything.”

Jack suddenly lost all of his air halfway into the 10-minute drive, forcing his mom to make to an impossible choice: pull over to give him CPR or keep rushing to the hospital.

Carlin decided to continue to the ER, knowing immediate resuscitation wouldn’t be enough, given Jack would need rapid intubation among other urgent procedures.

“I heard him slump over. I went to look back, and God said, ‘Maria, don’t look back. You made your decision. You’re not going to be able to handle seeing him right now,’ ” she recalled, fighting back tears.

“Knowing that you have a child in the back of your car who’s not breathing and needs CPR and not doing that for them — I don’t wish that scenario on my worst enemy.”

Carlin made the critical decision to drive Jack to the hospital instead of stopping to give him CPR.

Carlin blared her car horn as she pulled up the car to the doors of ER, and a team of doctors and nurses flew into action over Jack, who was now in cardiac arrest and without a heartbeat.

“I just saw this lifeless kid who had no pulse, who looked blue,” said emergency-room Dr. Jennifer Gibb, who rushed to Jack after hearing Carlin “screaming.”

“I didn’t know she was a nurse at the time,” Gibb said of Carlin.

“I heard her saying, ‘Come on, Jack,’ and that’s my son’s name. It sends chills through your spine when you’re helping this little child that could be your own,” said Gibb of her own 11-year-old son.

Jack’s pulse returned after the doctors and nurses worked on him for almost 10 minutes.

“I can’t even explain what that feeling is like when you know that your child’s heart is beating again,” Carlin said.

Jack was transferred to Cohen Children’s Medical Center a few hours later.

“I’ve been working here for 13 years, and I really only had a pediatric arrest like that, maybe about five times,” Gibb said.

Further examinations showed he had a laryngeal cleft, which impacts between 10,000 and 20,000 annual births, according to Northwell.

“It’s an abnormal opening in the back of the voice box that separates the voice box from the esophagus,” said Dr. Lee Smith, Cohen’s chief of pediatric otolaryngology.

Mucus or fluids can block airflow as a result of the “extremely uncommon” occurrence.

The boy’s dire situation was even more incredibly unique, according to Smith, who later performed his corrective surgery with no complications.

“I’ve never seen that before. … This was an extremely unusual and severe presentation,” Smith said of the boy losing lethal amounts of air.


Jack is now a happy, healthy pre-K-enrolled kid who, along with his mom, dad and siblings Luke and Emma, makes up a family incredibly grateful to the frontline workers who brought about their happy ending.

“The survival rate of a child going into cardiac arrest outside of a hospital is terrifyingly low,” Carlin said.

“After everything happened, I turned to my husband, and I was just like, ‘We’re going to Disney World. This child is going to experience Disney World.’ “8Jack told The Post he enjoyed his vacation and is happy in pre-K.


The Carlin family just returned from the Happiest Place on Earth, where Jack and his siblings and their dad Stewart got their fill of the magic they deserve after the mid-summer ordeal.

“I really liked the Slinky ride,” Jack told The Post.

“And I love being in school.”

Alex Mitchell

https://nypost.com/2025/11/19/us-news/li-moms-impossible-decision-saves-lifeless-child-and-reveals-exceptionally-rare-condition/

Monday, November 17, 2025

Skeletal muscle MRI patterns in female dystrophinopathy carriers

Vigliano AP, Luce L, Pastor Rueda JM, Chaves H, Mesa L, Carcione M, Mazzanti C, Llames Massini C, Radic CP, Cejas C, Giliberto F. Whole-Body Skeletal Muscle MRI Patterns in Female Dystrophinopathy Carriers. Neurol Genet. 2025 Sep 30;11(5):e200301. doi: 10.1212/NXG.0000000000200301. PMID: 41048923; PMCID: PMC12488845.

Abstract

Background and objectives: Dystrophinopathies are X-linked recessive diseases caused by pathogenic variants in the Duchenne muscular dystrophy (DMD) gene. Some women carrying a single DMD pathogenic variant manifest variable levels of symptomatology. Those who manifest severe and early-onset symptoms are considered to be affected by dystrophinopathy rather than carriers. The aim of this study was to characterize and compare muscle structure between female DMD carriers who were asymptomatic at the time of the study and female control participants using whole-body MRI (WB-MRI) and correlate the findings with clinical and genetic data.

Methods: We conducted a cross-sectional observational study comparing a group of female carriers of DMD pathogenic variants and a group of healthy noncarrier controls. The first group included obligate and genetically confirmed DMD female carriers, not classified as having dystrophinopathy. Women in the healthy group had no family history of DMD or other muscular dystrophies. All individuals underwent WB-MRI, which was evaluated using qualitative grading scales to assess muscle edema, trophism, and fatty infiltration. Neurologic examinations, serum creatine kinase measurement, DMD genetic screening, and X-chromosome inactivation studies were performed on the DMD carriers.

Results: The study included 29 DMD female carriers and 30 healthy noncarrier controls. All DMD carriers showed signs of muscle involvement on MRI, revealing a larger proportion of skeletal muscle involvement in carriers than in controls (85% vs 27% of 48 examined muscles/group of muscles, p < 0.001). Edema, fatty infiltration, and atrophy were more common in DMD carriers (62.5% vs 8%; 81% vs 35%; and 81% vs 25%, respectively, all p < 0.001), particularly in muscles of the calves, thighs, and pelvic region. The most frequently affected muscles were gastrocnemius, gluteus maximus, and soleus. No correlations were found between the MRI results and the clinical and genetic data.

Discussion: Our findings indicate that DMD female carriers who are asymptomatic at the time of our study may be at risk of developing muscle symptoms at a future time. Multidisciplinary surveillance of DMD female carriers will facilitate early detection and management of complications.